The RESOMER RG 502 Bioresorbable PLGA Drug Delivery Grade is a 50:50 poly(D,L-lactide-co-glycolide) with an ester-terminated chain architecture. The material is supplied as a white to off-white powder or granular solid, with a monomer ratio controlled to 48–52 mol% D,L-lactide and 48–52 mol% glycolide. Inherent viscosity is specified at 0.16–0.24 dL/g, measured at 0.1% w/v in chloroform at 25 °C under DIN EN ISO 1628-1. The glass transition temperature is commonly observed between 42 °C and 46 °C by differential scanning calorimetry using a second heating ramp of 10 K/min. The molecular weight is low relative to higher Resomer grades in the 50:50 series, which produces a low-shear solution viscosity in volatile organic solvents and a degradation period suited to short-to-medium parenteral release. Residual monomers are typically controlled to ≤0.5% w/w; certificates of analysis report batch-specific values for residual tin, residual solvents, water content, and molecular weight distribution. Because the polymer is bioresorbable, ester hydrolysis yields lactic acid and glycolic acid, and the degradation products are removed through normal metabolic pathways.

In application, RG 502 is used as a matrix polymer in solvent-evaporation microspheres, in situ forming implants, nanoparticles, and solvent-cast films. The ester-terminated structure gives a lower initial carboxylic acid content than the acid-terminated RG 502 H, which alters water uptake and the initial pH at the polymer-water interface. This distinction is critical when formulating acid-labile peptides or when an extended induction period before mass loss is undesirable. For formulations requiring release durations between 2 weeks and 8 weeks, the low inherent viscosity of RG 502 provides processing flexibility. For release beyond 8 weeks, higher molecular weight grades or lower glycolide ratios are generally substituted because the 50:50 backbone loses molecular weight more rapidly after hydration.

Batch release for the Drug Delivery Grade also includes residual solvent and residual tin control. Biocompatibility is not established by the raw polymer alone; the finished device is evaluated under ISO 10993-1, with cytotoxicity screening under ISO 10993-5, irritation and sensitization under ISO 10993-10, and systemic toxicity under ISO 10993-11 based on the intended route and exposure duration. Cold storage at -20 °C prevents premature hydrolysis, but the container must be allowed to reach ambient temperature under inert gas before opening. Opening a cold container in humid air above 60% RH causes surface water adsorption, which must be followed by vacuum drying before processing.

What Limits Solvent Selection and Residual Solvent Clearance?

Solvent selection for RG 502 is constrained by solubility, thermal stability of the polymer solution, and residual solvent clearance under ICH Q3C. The polymer dissolves readily in dichloromethane, chloroform, acetone, ethyl acetate, tetrahydrofuran, and dimethyl sulfoxide, but is insoluble in water, ethanol, and non-polar hydrocarbons. Dichloromethane is frequently used for oil-in-water microencapsulation because of its low boiling point and high polymer solubility. Under ICH Q3C, dichloromethane is assigned to Class 2 with a permitted daily exposure of 6.0 mg/day and a recommended residual limit of 600 ppm for a 10 g/day parenteral dose. Chloroform is limited to 60 ppm and is typically reserved for analytical viscosity measurement rather than production because of its higher toxicity. Ethyl acetate offers lower toxicological concern but slower solvent extraction and may induce phase separation if the aqueous phase is too cold or if polymer concentration exceeds 20% w/w.

Residual solvent removal after microsphere hardening is normally performed by vacuum evaporation with an aqueous-phase temperature ramp from 15 °C to 35 °C and an extended nitrogen sweep, followed by lyophilisation to a residual water content below 1.0% w/w. The low glass transition temperature of RG 502 prevents aggressive vacuum drying above 40 °C because particle sintering occurs; this is a processing boundary that higher molecular weight 50:50 grades can tolerate only slightly better. Drying above the glass transition fuses particles and shifts the particle size distribution toward larger agglomerates.

In oil-in-water emulsion processing, the polymer solution is dispersed into an aqueous phase containing 0.5–2.0% w/v polyvinyl alcohol. A rotor-stator homogenizer is operated at tip speeds above 10 m/s during the initial emulsification step. The low solution viscosity of RG 502 permits particle size reduction to 10–50 µm at lower energy input than is required for RG 503 or RG 504. Solvent extraction into the continuous phase drives polymer precipitation. The extraction rate must be balanced against drug partitioning: rapid extraction traps drug near the particle surface and increases burst release, whereas excessively slow extraction produces dense particles but can cause agglomeration.

The aqueous continuous phase is often buffered with phosphate or acetate at pH 5.0–7.4 because alkaline conditions above pH 8.0 accelerate hydrolysis and reduce encapsulation efficiency. Ethanol in the extraction bath is limited because ethanol collapses the particle matrix and can produce surface pitting. Residual dichloromethane is measured by headspace gas chromatography; acceptance limits follow ICH Q3C based on the daily dose. The low boiling point of dichloromethane causes evaporative cooling during emulsification; the vessel is therefore maintained at 15–20 °C to avoid premature polymer precipitation at the solvent-water interface.

In solvent-based microsphere manufacturing, the low inherent viscosity of RG 502 reduces the pressure drop through 0.2 µm sterilizing-grade filters and permits higher polymer solids in the dispersed phase. Spray drying of RG 502 from acetone or ethyl acetate can generate particles below 10 µm, but the inlet temperature is kept low to avoid particle fusion. Typical inlet temperatures for low-IV 50:50 PLGA are 45–60 °C; published data for RG 502-specific spray-drying limits is limited, so the range is applied only as a starting condition and must be confirmed by scanning electron microscopy. Fluidised-bed drying of spray-dried powder is limited by the glass transition temperature, with product temperature maintained below 35 °C. Because the material is hygroscopic, pre-drying under vacuum at 25 °C for 8–24 h is recommended when the powder has been stored outside a controlled dry environment. Residual water above 0.5% w/w accelerates hydrolysis during hot-melt extrusion and can lower molecular weight before implantation.

Hydrolytic degradation of RG 502 proceeds by bulk erosion. Water penetrates the matrix faster than ester bond scission, producing a relatively uniform molecular weight loss throughout the device rather than surface-controlled erosion. The low initial molecular weight means that the critical molecular weight for mass loss is reached earlier than for higher-IV grades. In 0.01 M phosphate-buffered saline at 37 °C and pH 7.4, lactic and glycolic acid release increases after an induction period. The induction period is shorter for acid-terminated RG 502 H and longer for ester-terminated RG 502 because the ester end cap reduces the initial concentration of catalytic carboxylic acid end groups. Inside large implants, the pH can drop below 3.0 and accelerate autocatalysis; in microspheres below 50 µm, degradation products diffuse out more rapidly and the internal pH drop is less severe.

Injectability, Viscosity, and Terminal Sterilization Boundaries

For in situ forming implants, RG 502 is dissolved in water-miscible solvents such as N-methyl-2-pyrrolidone or dimethyl sulfoxide at polymer concentrations between 20% w/w and 40% w/w. The low inherent viscosity of the grade provides lower injection force through 21G and 23G needles than higher-IV grades at equivalent polymer loading. Syringe force is influenced more by solvent choice and solution aging than by needle gauge; solutions should be prepared fresh and protected from atmospheric moisture because ester hydrolysis can alter viscosity during holding. Injection into an aqueous environment induces phase inversion and forms a depot. Formation of the depot at 37 °C in phosphate-buffered saline is accompanied by solvent exchange, and the low molecular weight of RG 502 produces a soft, flexible implant rather than a rigid monolith.

Terminal sterilisation of RG 502 formulations requires selection among gamma irradiation, ethylene oxide, and aseptic filtration. Gamma irradiation at 25 kGy reduces number-average molecular weight and increases the polydispersity index through chain scission; the effect is more pronounced for low-IV grades than for high-IV grades. Ethylene oxide processing at 40–60 °C and elevated relative humidity must be followed by aeration to remove residual ethylene oxide and ethylene chlorohydrin; however, the required humidity can accelerate hydrolysis of RG 502, particularly if the polymer has not been pre-dried. Aseptic filtration of low-viscosity organic solutions through 0.22 µm membranes is more feasible for RG 502 than for RG 504, but adsorption of peptide drugs onto the membrane can occur. Sterile hold time of the filtered solution is typically validated within 24–48 h to limit ester hydrolysis before use.

When Acid-Terminated RG 502 H Is Substituted for Ester-Terminated RG 502

Substitution of RG 502 by RG 502 H changes the initial carboxylic acid content and degradation profile, not the lactide/glycolide ratio or the inherent viscosity specification. The acid-terminated grade hydrates more rapidly at 37 °C and pH 7.4, and the local pH drop is more immediate. For basic drugs, the acid-terminated grade can form ion pairs that alter drug loading and release. The ester-terminated RG 502 is therefore preferred where lower initial acidity and a slightly longer induction period are required. Higher molecular weight grades such as RG 503 and RG 504 retain the same 50:50 monomer ratio but exhibit higher solution viscosity, slower mass loss, and longer release duration under identical microsphere conditions. Compared with 75:25 PLGA grades, RG 502 degrades faster because the higher glycolide content accelerates water uptake and ester backbone hydrolysis.

Differences between grades are evaluated by gel permeation chromatography for molecular weight distribution, by release testing under USP <711> Apparatus 4 flow-through cells, and by ISO 10993-5 cytotoxicity screening before animal studies. For release periods beyond 3 months, a 75:25 PLGA grade such as RG 752 H is used because the lower glycolide content slows bulk degradation. Under identical microsphere emulsification, higher-IV 50:50 grades produce larger particles and higher encapsulation of hydrophobic drugs. The selection of RG 502 over RG 502 H or over higher molecular weight grades is therefore based on the required lag time, drug-polymer compatibility, solution viscosity, and target release interval.